Soluble HLA-E Trimolecular Complexes for Tuberculosis Ligand Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying Mycobacterium tuberculosis (Mtb)-derived peptide ligands presented by HLA molecules are inefficient, resulting in low yields, impurity, and ambiguity, limiting the effectiveness of diagnostic and therapeutic approaches for tuberculosis.
Innovation Solution
A deep ligand sequencing workflow involving the purification and mass spectrometric analysis of soluble HLA molecules from infected cells to identify and sequence Mtb-specific peptide ligands, providing high-confidence and pure preparations of HLA ligands that can be used as biomarkers and therapeutic targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional methods (T cell lines or predictive algorithms) are used to identify Mtb-specific peptide ligands, then the process is simpler to perform, but the results suffer from low yield, impurity, and ambiguity
Solution Approach 1:
The workflow is segmented into distinct functional modules: soluble HLA expression system, peptide elution from HLA complexes, fractionation by high-pH reverse phase chromatography, and identification by mass spectrometry. Each module addresses specific challenges independently, improving overall purity while managing complexity through modular design
Solution Approach 2:
Soluble HLA molecules serve as an intermediary carrier that binds Mtb-specific peptide ligands with high specificity. This intermediary enables the isolation and purification of peptide ligands from complex cellular environments, achieving high purity identification that would be impossible through direct screening methods
2Productivity
If T cell lines are used to screen for biologically active ligands, then biological relevance is maintained, but the throughput and productivity are low
Solution Approach 1:
The patent replaces biological screening systems (T cell lines) with a biophysical identification system based on mass spectrometry and chromatography. This substitution dramatically increases throughput and productivity while reducing the quantity of biological materials required, as the method directly identifies peptide sequences without requiring functional biological assays
Solution Approach 2:
The method creates a reproducible soluble HLA expression system that can be scaled up to produce large quantities of HLA-peptide complexes. This copying approach allows high-throughput processing of multiple HLA types and peptide ligands simultaneously, overcoming the low throughput limitation of T cell line screening
3Measurement precision
If predictive algorithms are used to identify binding peptides, then the initial screening is faster, but the accuracy and confidence in ligand identification are reduced
Solution Approach 1:
The patent performs preliminary enrichment of Mtb-specific peptide ligands by exploiting their specific binding to soluble HLA molecules. This preliminary action concentrates the target peptides from complex mixtures before mass spectrometry analysis, achieving high-confidence identification without requiring extensive synthesis and testing of predicted peptides
Solution Approach 2:
The method incorporates iterative optimization where mass spectrometry data is used to refine and validate predicted peptide-HLA binding motifs. This feedback loop increases measurement precision and confidence in ligand identification, while reducing the need for extensive experimental verification of false predictions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the identification of novel Mtb-specific peptide epitopes that can be used for diagnostics, vaccine development, and targeted therapies, applicable to the entire human population due to the monomorphic nature of HLA-E, overcoming the limitations of previous methods.
Implementation Method 1
Class I major histocompatibility complex (MHC) molecules, designated class I HLA in humans, bind and display peptide antigen ligands upon the cell surface
Implementation Method 2
A deep ligand sequencing workflow involving the purification and mass spectrometric analysis of soluble HLA molecules from infected cells to identify and sequence Mtb-specific peptide ligands
Data Source
AI summary
Compositions that include one isolated, class I HLA-E trimolecular complex that includes a peptide ligand unique to M. tuberculosis-infected cells are disclosed. Isolated compositions that include the three components of the trimolecular complex and/or a polynucleotide encoding one or more of the three components are also disclosed.